Oncolytics Biotech, Inc. (ONCY)
0.5033
+0.01
(+1.04%)
USD |
NASDAQ |
Oct 19, 14:46
Oncolytics Biotech Cash from Operations (Annual) : -20.11M for Dec. 31, 2025
Cash from Operations (Annual) Chart
Historical Cash from Operations (Annual) Data
| Date | Value |
|---|---|
| December 31, 2025 | -20.11M |
| December 31, 2024 | -19.88M |
| December 31, 2023 | -21.08M |
| December 31, 2022 | -17.94M |
| December 31, 2021 | -17.89M |
| December 31, 2020 | -16.45M |
| December 31, 2019 | -15.00M |
| December 31, 2018 | -9.197M |
| December 31, 2017 | -11.47M |
| December 31, 2016 | -9.418M |
| December 31, 2015 | -11.75M |
| December 31, 2014 | -17.82M |
| December 31, 2013 | -23.72M |
| December 31, 2012 | -34.27M |
| Date | Value |
|---|---|
| December 31, 2011 | -22.78M |
| December 31, 2010 | -17.36M |
| December 31, 2009 | -14.09M |
| December 31, 2008 | -14.33M |
| December 31, 2007 | -13.44M |
| December 31, 2006 | -10.72M |
| December 31, 2005 | -9.121M |
| December 31, 2004 | -7.089M |
| December 31, 2003 | -3.912M |
| December 31, 2002 | -4.621M |
| December 31, 2001 | -2.759M |
| December 31, 2000 | -2.126M |
| December 31, 1999 | -0.3597M |
Cash From Operations Definition
Represents the net cash flow from the company's business operations.
Cash from Operations (Annual) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Operations (Annual) Benchmarks
| Revolution Medicines, Inc. | -897.74M |
| Arrowhead Pharmaceuticals, Inc. | 179.55M |
| Sangamo Therapeutics, Inc. | -97.21M |
| Sarepta Therapeutics, Inc. | -222.54M |
| Anixa Biosciences, Inc. | -7.173M |